Bone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-like growth factor and hypoxia
==============================================================================================================================

Bone is one of the most common sites of malignant spread in cancer, yet little is understood about the process. In this study by Kuchimaru and colleagues, cancer cells were injected into mouse models at the same time as a number of variables to investigate in what microenvironment bone metastases would most likely occur. The researchers found that receptor activator of factor-κB ligand promoted the colonization of osteosarcoma cancer cells through the cooperative effects of insulin-like growth factor 1, released during bone resorption, and activation of hypoxia-inducible factor in the hypoxic bone marrow microenvironment. This study lays the groundwork for further understanding the elusive process of bone metastases. doi: [10.1111/cas.12391](10.1111/cas.12391)

![](cas0105-0iii-f1){#d35e59}

Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors
==========================================================================================================================================================

Diffuse-type gastric carcinoma (DGC) is an especially potent type of a stomach cancer that carries a worse prognosis than other gastric carcinomas. In an effort to identify potential targets for chemotherapeutic agents, Yamaguchi et al. studied tyrosine kinase activity in a panel of DGC cell lines. They discovered that although Met seems to be upregulated in DGC, only a subset of DGCs were sensitive to Met inhibitors. A similar picture was true for lines that upregulated fibroblast growth factor receptor 2. Amazingly, cell lines that were insensitive to both Met and fibroblast growth factor receptor 2 inhibitors were sensitive to saracatinib, a tyrosine kinase inhibitor that targets Src. This exciting new work paves the way for continued exploration of targeted chemotherapeutic options for DGC. doi: [10.1111/cas.12387](10.1111/cas.12387)
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Identification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cells
==================================================================================================================================

Tumors often outgrow their blood supply and require the formation of new blood vessels to support their cellular functions. A common target for antitumor growth is angiogenesis, because the inhibition of new blood vessel formation can impair the propagation of tumor cells. However, therapeutic methods in current practice are not directed at tumor-specific angiogenesis. In this exceptional work, Otsubo and coworkers used microarray analyses and siRNA techniques to isolate potential tumor-specific angiogenenic markers. The researchers developed their work further by identifying two such markers upregulated in human renal cell carcinoma specimens. The markers identified in this study have the potential to act as targets for novel therapeutic interventions and the work more broadly opens doors for additional research into other markers for a variety of cancer types. doi: [10.1111/cas.12394](10.1111/cas.12394)
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